Core Insights - The partnership between the Ladies Professional Golf Association (LPGA) and Ardelyx aims to educate and mobilize patients regarding digestive health, particularly focusing on women suffering from irritable bowel syndrome with constipation (IBS-C) [1][2] Group 1: Partnership Overview - Ardelyx has been named the official corporate pharmaceutical Marketing Partner of the LPGA Tour, marking a first-of-its-kind collaboration [1] - The partnership seeks to empower women to take control of their health and engage in open conversations about digestive health [2] Group 2: Health Focus - Women represent over 90% of individuals living with IBS-C, yet many face stigma and lack awareness, leading to isolation [2] - The collaboration aims to redefine discussions around IBS-C, emphasizing the importance of mental health, relationships, and work productivity affected by the condition [2] Group 3: Engagement Strategies - Ardelyx will implement a 360-degree approach to engage with the LPGA audience, including onsite experiences, storytelling, hospitality, and digital engagement [3] - The partnership will utilize LPGA platforms to distribute original digital and social content aimed at educating and connecting patients [2][3] Group 4: Organizational Background - The LPGA, established in 1950, is the premier women's professional golf organization, representing nearly 40 countries and providing opportunities for female golfers [4] - Ardelyx focuses on developing innovative medicines to address significant unmet medical needs, with two commercial products approved in the U.S. [6][7]

Core Insights - Ardelyx, Inc. presented data on XPHOZAH at the American Society of Nephrology's Kidney Week, highlighting its effectiveness in real-world settings for patients with chronic kidney disease on dialysis [1][3] Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on developing innovative medicines to address significant unmet medical needs [1][15] - The company has two commercial products approved in the United States: IBSRELA and XPHOZAH, with ongoing development of next-generation therapies [15][16] Product Information - XPHOZAH is the first phosphate absorption inhibitor approved by the FDA for reducing serum phosphorus in adults with chronic kidney disease on dialysis [2][14] - It is administered as a single tablet taken twice daily and works by blocking phosphate absorption in the gut [2][10] Clinical Study Results - The first real-world study of XPHOZAH showed that patients experienced an average reduction in serum phosphate of nearly 1 mg/dL, with 45.3% of participants achieving a reduction of ≥1 mg/dL [3][4] - A separate survey indicated that 63% of patients reported improved phosphate levels since starting tenapanor, with 69% feeling better about their phosphate control [4] Patient Experience - Positive patient experiences were reported, including improved bowel movements and lower pill burden, with 44% attributing improvements to better phosphate control [4] - Tenapanor also demonstrated effectiveness in improving bowel movements in patients with end-stage kidney disease and constipation [6][7] Economic Analysis - A cost-effectiveness analysis in Japan concluded that tenapanor is cost-effective for hemodialysis patients, meeting the threshold of five million Japanese Yen for willingness to pay [8]

Core Insights - Ardelyx, Inc. is participating in a fireside chat at the Jefferies Global Healthcare Conference in London on November 19, 2025 [1] - The company focuses on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs [3] Company Overview - Ardelyx has two commercial products approved in the United States: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) [3] - The company is developing RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas [3] - Ardelyx has international agreements for the commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3] - Knight Therapeutics is responsible for commercializing IBSRELA in Canada [3]

Core Insights - Ardelyx, Inc. is focused on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs [3] Company Overview - Ardelyx has two commercial products approved in the United States: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) [3] - The company is developing RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas [3] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3] - Knight Therapeutics is responsible for commercializing IBSRELA in Canada [3] Upcoming Events - The President and CEO of Ardelyx, Mike Raab, will participate in a fireside chat at the Wedbush Rewind ASN 2025 Conference on November 10, 2025 [1] - A public webcast of the event will be available on the Ardelyx website, with a replay accessible for 30 days post-event [2]

Core Insights - Ardelyx, Inc. is set to hold a conference call on August 4, 2025, to discuss its financial results and provide a business update for Q2 2025 [1] Company Overview - Ardelyx is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [3] - The company has two commercial products approved in the U.S.: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) [3] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3] - Knight Therapeutics is responsible for commercializing IBSRELA in Canada [3]

Core Insights - Ardelyx, Inc. has appointed Merdad Parsey, M.D., Ph.D. to its board of directors, enhancing its leadership team with a veteran biotech expert [1][2] Company Overview - Ardelyx is focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [4] - The company has two commercial products approved in the U.S.: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor), along with early-stage pipeline candidates [4] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [4] Leadership Experience - Dr. Parsey brings over 25 years of experience in the pharmaceutical and biopharma industries, having held various clinical development and leadership roles [2][3] - His recent position was Chief Medical Officer at Gilead Sciences from 2019 until his retirement in 2025 [2] - Dr. Parsey has also served in senior roles at Genentech and as CEO of 3-V Biosciences, contributing to his extensive expertise in clinical strategy and development [2] Educational Background - Dr. Parsey holds a B.S. in microbiology and biochemistry, an M.D., and a Ph.D. in immunology from the University of Maryland [3] - He completed his internal medicine residency at Stanford University and a fellowship in pulmonary and critical care at the University of Colorado [3]

Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [3] - The company has two commercial products approved in the United States: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) [3] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3] Upcoming Events - Ardelyx will hold a conference call on May 1, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update for the first quarter of 2025 [1] - Participants can join the call by dialing (877) 346-6112 for domestic calls or (848) 280-6350 for international calls [2] - The conference call will be available via live audio webcast on the company's website and will be archived for 30 days [2]

Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [1][12] - The company has two commercial products approved in the United States: IBSRELA and XPHOZAH, both containing the active ingredient tenapanor [12] Product Information - XPHOZAH (tenapanor) is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. FDA for reducing serum phosphorus in adults with chronic kidney disease (CKD) on dialysis [2][11] - It is indicated as add-on therapy for patients who have an inadequate response to phosphate binders or are intolerant to any dose of phosphate binder therapy [11] - XPHOZAH operates through a unique mechanism that blocks phosphate absorption at the primary pathway and is administered as a single tablet taken twice daily [2][6] Clinical Study Insights - The OPTIMIZE Study was a randomized, open-label trial involving 330 patients with CKD on dialysis and hyperphosphatemia, aimed at evaluating methods for initiating XPHOZAH to optimize phosphorus management [3] - A post-hoc analysis of this study has been accepted for presentation at the National Kidney Foundation Spring Clinical Meetings [1][4] Safety and Efficacy - Diarrhea was the most common side effect reported in clinical trials, occurring in 43-53% of patients, with severe diarrhea reported in 5% of patients [10] - The majority of diarrhea events were mild-to-moderate and typically resolved over time or with dose reduction [10] Industry Context - Hyperphosphatemia is a serious condition affecting the majority of the 550,000 patients in the U.S. with CKD on maintenance dialysis, necessitating effective management strategies [7] - The KDIGO treatment guidelines recommend lowering elevated phosphate levels toward the normal range of 2.5-4.5 mg/dL [7]